Hikal Ltd.

View in App
322.25 -3.35 ▼-1.0%

07 June 2023, 04:01:00 PM
Volume: 17,297

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hikal.com
Market Cap 3,973.37 Cr.
Enterprise Value(EV) 4,661.78 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 6.36 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 50.69 Trailing Twelve Months Ending 2023-03
Industry PE 33.94 Trailing Twelve Months Ending 2023-03
Book Value / Share 91.93 Trailing Twelve Months Ending 2023-03
Price to Book Value 3.51 Calculated using Price: 322.25
Dividend Yield 0.37 Period Ending 2022-03
No. of Shares Subscribed 12.33 Cr. 123,300,750 Shares
FaceValue 2
About Hikal Ltd.
Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Hikal Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Hikal Ltd. Performance

View details >>
1 Day
-1.03%
1 Week
+5.59%
1 Month
+6.69%
3 Month
+5.90%
6 Month
-16.27%
1 Year
+8.63%
2 Year
-35.90%
5 Year
+109.84%
10 Year
+508.71%

Hikal Ltd. Fundamental Ratios

View details >>
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 17.27 9.81 9.32 12.74 12.12 14.46 10.74 15.22 16.04
Return on Capital Employed (%) 17.77 12.50 11.92 11.87 12.81 15.25 12.44 16.15 15.21
Return on Assets (%) 5.17 3.12 3.17 5.02 5.15 6.11 4.62 6.84 7.39

Hikal Ltd. Balance Sheet

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 505 532 564 605 669 756 817 933 1,068 1,133
Non Curr. Liab. 298 242 337 324 312 359 410 379 432 590
Curr. Liab. 479 530 397 470 616 659 653 703 828 662
Minority Int.
Equity & Liab. 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,328 2,385
Non Curr. Assets 775 791 808 793 851 888 1,048 1,091 1,305 1,446
Curr. Assets 507 513 490 607 746 886 831 925 1,023 939
Misc. Exp. not W/O
Total Assets 1,282 1,304 1,298 1,400 1,597 1,775 1,879 2,016 2,328 2,385

Hikal Ltd. Profit and Loss

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 829 872 926 1,014 1,296 1,590 1,507 1,720 1,943 2,023
Other Income 34 2 2 3 4 2 4 5 5 7
Total Income 863 873 927 1,017 1,301 1,592 1,511 1,725 1,948 2,030
Total Expenditure -642 -689 -745 -815 -1,054 -1,291 -1,234 -1,398 -1,602 -1,768
PBIDT 221 184 183 202 246 300 277 328 345 262
Interest -68 -60 -62 -48 -49 -58 -52 -36 -31 -48
Depreciation -55 -64 -67 -69 -86 -93 -82 -85 -96 -109
Taxation -34 -19 -12 -13 -34 -46 -42 -73 -58 -27
Exceptional Items -4 -15
PAT 64 40 41 68 77 103 84 133 161 78
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 64 40 41 68 77 103 84 133 161 78
Adjusted EPS 5 3 3 5 6 8 7 11 13 6

Hikal Ltd. Cash Flow

View details >>
Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 61 154 102 186 163 139 186 285 229 294
Cash Fr. Inv. -28 -23 -43 -64 -102 -110 -125 -164 -156 -284
Cash Fr. Finan. -27 -124 -69 -124 -63 -25 -55 -101 -97 -6
Net Change 6 7 -10 -2 -2 4 6 20 -24 4
Cash & Cash Eqvt 9 16 6 4 2 6 11 32 8 11

Hikal Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 68.77 68.77 68.77 68.77 68.77 68.77 68.77 68.83 68.85
Public 31.23 31.23 31.23 31.23 31.23 31.23 31.23 31.17 31.15
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Hikal Ltd. Announcements

View details >>
Fri, 02 Jun 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of Earnings call for quarter and financial year ended March 31 2023
Thu, 01 Jun 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyHIKAL LTD.
2CIN NO.L24200MH1988PTC048028
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 545.62
4Highest Credit Rating during the previous FY A+
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Rajasekhar Reddy
Designation: Company Secretary and Compliance Officer
EmailId: rajasekhar_reddy@hikal.com
Name of the Chief Financial Officer: Kuldeep Jain
Designation: Chief Financial Officer
EmailId: kuldeep_jain@hikal.com

Date: 01/06/2023

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Wed, 31 May 2023
Announcement Under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation of officials of the Company in the Conference organised by B and K Securities.

Hikal Ltd. Technical Scans

View details >>
Wed, 07 Jun 2023
Close Above Last Month High Close Above Last Month High
High Increase in 1 Month High Increase in 1 Month
High Increase in 5 Years High Increase in 5 Years
CCI Overbought Zone CCI Overbought Zone
Tue, 06 Jun 2023
Close Crossing Last Week High Close Crossing Last Week High

Hikal Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 243,352.55 1,014.25 +0.1%
Divi's Laboratories Ltd. 93,917.47 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. 77,796.29 4,671.20 +0.8%
Cipla Ltd. 77,533.91 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. 72,256.82 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. 61,011.56 1,802.70 +0.8%
Mankind Pharma Ltd. 59,547.47 1,486.50 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.72 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 51.51 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.26 4,671.20 +0.8%
Cipla Ltd. Consolidated 2023-03 27.67 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 88.22 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 49.01 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 46.45 1,486.50 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.35 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7.36 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.34 4,671.20 +0.8%
Cipla Ltd. Consolidated 2023-03 3.31 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.67 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.84 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 5.68 1,486.50 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,671.20 +0.8%
Cipla Ltd. Consolidated 2022-03 0.04 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2022-03 0.14 1,486.50 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,671.20 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2022-03 26.72 1,486.50 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,671.20 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2022-03 26.72 1,486.50 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,671.20 +0.8%
Cipla Ltd. Consolidated 2022-03 21,763.34 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2022-03 7,781.56 1,486.50 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,014.25 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,537.80 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,671.20 +0.8%
Cipla Ltd. Consolidated 2022-03 2,559.47 960.50 -1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 5,025.35 +1.7%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,802.70 +0.8%
Mankind Pharma Ltd. Consolidated 2022-03 1,452.96 1,486.50 -0.2%

Hikal Ltd. FAQ's

What is Hikal share price?
Can I buy Hikal shares now?
What is the Dividend Yield of Hikal?
What is the Market Cap of Hikal?
What are the key metrics to analyse Hikal?
What is the 52 Week High and Low of Hikal?
What is the trend of Hikal share price?